eligibility_summary
Adults (≥18) with advanced GI cancers (esophageal, gastric, pancreatic, colorectal) after ≥2nd-line failure/unsuitable, ECOG 0–1, life expectancy ≥3 months, RECIST-measurable disease, biopsy-confirmed target within 3 years, adequate organ/marrow function, venous access for apheresis, contraception. Exclude active CNS mets, active HBV/HCV/HIV, severe autoimmune, infections, unstable cardiac/organ disease, recent surgery/therapy, other recent cancers, recent CAR-T, GVHD, systemic steroids, allergy, anticoagulation, pregnancy.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
manual_review_required
ai_summary
Trial tests BGT007H cells, a biological cell therapy (adoptive immunotherapy) given by IV in escalating doses (1.0×10^8 to 3.0×10^9 cells). Patients must have tumors positive for a predefined target. Mechanism of action: antigen-directed adoptive cell transfer—ex vivo engineered/expanded immune effector cells (likely autologous T cells) recognize the tumor-associated target, then mediate cytotoxic killing and cytokine-driven immune activation, PK assesses in vivo expansion/persistence. Targeted cells/pathways: tumor cells in GI cancers (esophageal, gastric, pancreatic, colorectal) that express the study antigen (specific antigen not disclosed), engagement of T-cell receptor/CAR-like signaling and downstream cytolytic pathways leading to tumor cell lysis.